Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.60M | 75.90M | 139.50M | -131.60M | -190.60M |
| Total Depreciation and Amortization | 95.80M | 98.30M | 101.30M | 106.30M | 108.80M |
| Total Amortization of Deferred Charges | 9.80M | 9.40M | 200.00K | 2.80M | 7.40M |
| Total Other Non-Cash Items | 34.80M | 19.10M | -29.30M | 65.10M | 44.40M |
| Change in Net Operating Assets | -22.40M | -189.70M | -42.70M | 67.50M | 88.70M |
| Cash from Operations | 170.60M | 13.00M | 169.00M | 110.10M | 58.70M |
| Capital Expenditure | -13.80M | -11.60M | -14.00M | -15.70M | -22.90M |
| Sale of Property, Plant, and Equipment | 38.20M | 38.50M | 46.10M | 46.00M | 7.90M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 110.20M | 110.20M | 110.20M |
| Other Investing Activities | 45.00M | 75.00M | 75.00M | 55.00M | 30.00M |
| Cash from Investing | 69.40M | 101.90M | 217.30M | 195.50M | 125.20M |
| Total Debt Issued | -- | 0.00 | 219.00M | 234.00M | 284.00M |
| Total Debt Repaid | -112.50M | -6.90M | -413.00M | -473.50M | -482.40M |
| Issuance of Common Stock | 2.20M | 1.80M | 10.90M | 10.90M | 10.80M |
| Repurchase of Common Stock | -26.30M | -17.10M | -8.20M | -1.30M | -1.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 4.70M | -1.20M | -1.20M |
| Cash from Financing | -136.60M | -22.20M | -186.60M | -231.10M | -190.00M |
| Foreign Exchange rate Adjustments | 100.00K | 100.00K | 300.00K | -700.00K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.50M | 92.80M | 200.00M | 73.80M | -6.10M |